The DOI matches its Crossref record; 246 of the 246 references it cites were found in a registry or an index.
Long term hormone therapy for perimenopausal and postmenopausal women
Open accessAbstract
BACKGROUND: Hormone therapy (HT) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women. This is an updated version of a Cochrane review first published in 2005. OBJECTIVES: To assess effects of long-term HT (at least 1 year's duration) on mortality, cardiovascular outcomes, cancer, gallbladder disease, fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment. SEARCH METHODS: We searched the following databases to September 2016: Cochrane Gynaecology and Fertility Group Trials Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and PsycINFO. We searched the registers of ongoing trials and reference lists provided in previous studies and systematic reviews. SELECTION CRITERIA: We included randomised double-blinded studies of HT versus placebo, taken for at least 1 year by perimenopausal or postmenopausal women. HT included oestrogens, with or without progestogens, via the oral, transdermal, subcutaneous or intranasal route. DATA COLLECTION AND ANALYSIS: Two review authors independently selected studies, assessed risk of bias and extracted data. We calculated risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data, along with 95% confidence intervals (CIs). We assessed the quality of the evidence by using GRADE methods. MAIN RESULTS: We included 22 studies involving 43,637 women. We derived nearly 70% of the data from two well-conducted studies (HERS 1998; WHI 1998). Most participants were postmenopausal American women with at least some degree of comorbidity, and mean participant age in most studies was over 60 years. None of the studies focused on perimenopausal women.In relatively healthy postmenopausal women (i.e. generally fit, without overt disease), combined continuous HT increased the risk of a coronary event (after 1 year's use: from 2 per 1000 to between 3 and 7 per 1000), venous thromboembolism (after 1 year's use: from 2 per 1000 to between 4 and 11 per 1000), stroke (after 3 years' use: from 6 per 1000 to between 6 and 12 per 1000), breast cancer (after 5.6 years' use: from 19 per 1000 to between 20 and 30 per 1000), gallbladder disease (after 5.6 years' use: from 27 per 1000 to between 38 and 60 per 1000) and death from lung cancer (after 5.6 years' use plus 2.4 years' additional follow-up: from 5 per 1000 to between 6 and 13 per 1000).Oestrogen-only HT increased the risk of venous thromboembolism (after 1 to 2 years' use: from 2 per 1000 to 2 to 10 per 1000; after 7 years' use: from 16 per 1000 to 16 to 28 per 1000), stroke (after 7 years' use: from 24 per 1000 to between 25 and 40 per 1000) and gallbladder disease (after 7 years' use: from 27 per 1000 to between 38 and 60 per 1000) but reduced the risk of breast cancer (after 7 years' use: from 25 per 1000 to between 15 and 25 per 1000) and clinical fracture (after 7 years' use: from 141 per 1000 to between 92 and 113 per 1000) and did not increase the risk of coronary events at any follow-up time.Women over 65 years of age who were relatively healthy and taking continuous combined HT showed an increase in the incidence of dementia (after 4 years' use: from 9 per 1000 to 11 to 30 per 1000). Among women with cardiovascular disease, use of combined continuous HT significantly increased the risk of venous thromboembolism (at 1 year's use: from 3 per 1000 to between 3 and 29 per 1000). Women taking HT had a significantly decreased incidence of fracture with long-term use.Risk of fracture was the only outcome for which strong evidence showed clinical benefit derived from HT (after 5.6 years' use of combined HT: from 111 per 1000 to between 79 and 96 per 1000; after 7.1 years' use of oestrogen-only HT: from 141 per 1000 to between 92 and 113 per 1000). Researchers found no strong evidence that HT has a clinically meaningful impact on the incidence of colorectal cancer.One trial analysed subgroups of 2839 relatively healthy women 50 to 59 years of age who were taking combined continuous HT and 1637 who were taking oestrogen-only HT versus similar-sized placebo groups. The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT: Their absolute risk remained low, at less than 1/500. However, other differences in risk cannot be excluded, as this study was not designed to have the power to detect differences between groups of women within 10 years of menopause.For most studies, risk of bias was low in most domains. The overall quality of evidence for the main comparisons was moderate. The main limitation in the quality of evidence was that only about 30% of women were 50 to 59 years old at baseline, which is the age at which women are most likely to consider HT for vasomotor symptoms. AUTHORS' CONCLUSIONS: Women with intolerable menopausal symptoms may wish to weigh the be
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–246 of 246
Obiorah, I. E., & Jordan, V. C. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31828865a5 · Cited by 41
Herrington, D. M., Fong, J., Sempos, C. T., Black, D. M., Schrott, H. G., Rautaharju, P. M., Bachorik, P. S., Blumenthal, R. S., Khan, S. S., & WENGER, N. K. (1998) · American Heart Journal · doi:10.1016/s0002-8703(98)70191-7 · Cited by 41
Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study
Nielsen, T. F., Ravn, P., Pitkin, J., & Christiansen, C. (2006) · Maturitas · doi:10.1016/j.maturitas.2005.04.003 · Cited by 40
Hall, G., Pripp, U., Schenck-Gustafsson, K. G., & Landgren, B. (1998) · Maturitas · doi:10.1016/s0378-5122(97)00080-7 · Cited by 40
Notelovitz, M., John, V. A., & Good, W. R. (2002) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200209000-00007 · Cited by 40
Chen, F.-P., Lee, N., Soong, Y.-K., & Huang, K. (2001) · Menopause The Journal of The North American Menopause Society · doi:10.1097/00042192-200109000-00009 · Cited by 39
Zhao, S., Chlebowski, R. T., Anderson, G. L., Kuller, L. H., Manson, J. E., Gass, M. L. S., Patterson, R. E., Rohan, T. E., Lane, D. S., Beresford, S. A. A., et al. (2014) · Breast Cancer Research · doi:10.1186/bcr3632 · Cited by 39
Menopausal hormone therapy and breast cancer mortality: clinical implications
Chlebowski, R. T., & Anderson, G. L. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614568300 · Cited by 38
Estrogen after ischemic stroke: Clinical basis and design of The Women's Estrogen for Stroke Trial
Kernan, W. N., Brass, L. M., Viscoli, C. M., Sarrel, P. M., Makuch, R., & Horwitz, R. I. (1998) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/s1052-3057(98)80026-8 · Cited by 36
Short-term Menopausal Hormone Therapy for Symptom Relief: An Updated Decision Model
Col, N. F., Weber, G. M., Stiggelbout, A. M., Chuo, J., D’Agostino, R. B., & Corso, P. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.15.1634 · Cited by 35
Endothelial function in women of the Kronos Early Estrogen Prevention Study
Kling, J. M., Lahr, B. A., Bailey, K. R., Harman, S. M., Miller, V. M., & Mulvagh, S. L. (2014) · Climacteric · doi:10.3109/13697137.2014.986719 · Cited by 35
Christiansen, C., Christensen, M. S., Hagen, C., STOCKLUND, K., & Transbøl, I. (1981) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016348109154135 · Cited by 35
Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials
Mirkin, S., Pinkerton, J. V., Kagan, R., Thompson, J. R., Pan, K., Pickar, J. H., Komm, B. S., & Archer, D. F. (2016) · Journal of Women s Health · doi:10.1089/jwh.2015.5351 · Cited by 35
Wharton, W., Gleason, C. E., Dowling, N. M., Carlsson, C. M., Brinton, E. A., Santoro, M. N., Neal-Perry, G. S., Taylor, H. S., Naftolin, F. N., Løbo, R. A., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130245 · Cited by 34
Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes
Espeland, M. A., Brinton, R. D., Manson, J. E., Yaffe, K. S., Hugenschmidt, C. E., Vaughan, L., Craft, S., Edwards, B. J.-A., Casanova, R., Masaki, K., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001816 · Cited by 34
Os, I., Hofstad, A.-E., Brekke, M., Abdelnoor, M., Nesheim, B. I., Jacobsen, A. F., Birkeland, K. I., Larsen, A., Midtbø, K., & Westheim, A. S. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00675.x · Cited by 34
Teede, H. J., Liang, Y.-L., Kotsopoulos, D., Zoungas, S., Craven, R., & McGrath, B. P. (2002) · Climacteric · doi:10.1080/cmt.5.2.160.169 · Cited by 32
Pedersen, A. T. (2003) · Human Reproduction · doi:10.1093/humrep/deg435 · Cited by 29
Baseline Characteristics of the PEPI Participants
Miller, V. (1995) · Controlled Clinical Trials · doi:10.1016/0197-2456(94)00113-h · Cited by 29
Diem, S., Grady, D., Quan, J., Vittinghoff, E., Wallace, R., Hanes, V., & Ensrud, K. (2006) · Menopause · doi:10.1097/01.gme.0000192439.82491.24 · Cited by 28
Sl, C., Rm, R., Caubel, P., & Lim, P. (1999) · PubMed · Cited by 28
Exogenous reproductive hormone use in breast cancer survivors and previvors
Vaz-Luís, I., & Partridge, A. H. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.207 · Cited by 28
Vaughan, L., Espeland, M. A., Snively, B. M., Shumaker, S. A., Rapp, S. R., Shupe, J., Robinson, J. G., Sarto, G. E., & Resnick, S. M. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.047 · Cited by 27
Paoletti, A. M., Cagnacci, A., Carlo, C. D., Orrù, M., Neri, M., D’Alterio, M. N., & Melis, G. B. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2014.1003294 · Cited by 27
Climacteric vasomotor symptoms do not imply autonomic dysfunction
Virtanen, I., Polo‐Kantola, P., Erkkola, R. U., Polo, O. J., & Ekholm, E. M. K. (1999) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1999.tb08216.x · Cited by 25
Women's Angiographic Vitamin and Estrogen trial:
Hsia, J. A., Alderman, E. L., Verter, J. I., Rogers, W. J., Thompson, P. D., Howard, B. V., Cobb, F. R., Ouyang, P., Tardif, J., Higginson, L., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00237-4 · Cited by 24
Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial
Veerus, P., Fischer, K., Hovi, S., Karro, H., Rahu, M., & Hemminki, E. (2008) · BMC Women s Health · doi:10.1186/1472-6874-8-5 · Cited by 24
Unopposed Estradiol Therapy in Postmenopausal Women
Steiner, A. Z., Xiang, M., Mack, W. J., Shoupe, D., Felix, J. C., Løbo, R. A., & Hodis, H. N. (2007) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000251518.56369.eb · Cited by 24
Ovarian cancer patients and hormone replacement therapy: a systematic review
Hopkins, M. L., Fung, M. F. K., Le, T. V., & Shorr, R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.044 · Cited by 24
Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative
Chlebowski, R. T., Aragaki, A. K., & Anderson, G. L. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0106 · Cited by 24
Post, M. S., van der Mooren, M. J., van Baal, W. M., Neele, S. J. M., Netelenbos, J. C., & Kenemans, P. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.117340 · Cited by 22
Reboussin, B. A., Greendale, G. A., & Espeland, M. A. (1998) · Climacteric · doi:10.3109/13697139809085538 · Cited by 22
Bibbins-Domingo, K. B., Lin, F., Vittinghoff, E., Barrett-Connor, E. L., Hulley, S. B., Grady, D. G., & Shlipak, M. G. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.021 · Cited by 21
The ERA trial: findings and implications for the future
Nair, G. V., & Herrington, D. M. (2000) · Climacteric · doi:10.1080/13697130008500132 · Cited by 21
Effects of Long-Term Transdermal Administration of Estradiol on Serum Lipids
Ory, S. J., Field, C. S., Herrmann, R. R., Zinsmeister, A. R., & Riggs, B. L. (1998) · Mayo Clinic Proceedings · doi:10.4065/73.8.735 · Cited by 21
The ‘Timing Hypothesis’ for Estrogen Therapy in Menopausal Symptom Management
Manson, J. E. (2015) · Women s Health · doi:10.2217/whe.15.24 · Cited by 18
Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]
Vorobjov, S., Hovi, S., Veerus, P., Pisarev, H., Rahu, M., & Hemminki, E. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.05.001 · Cited by 17
Jm, A., Hart, D. M., Lindsay, R. J., Jb, A., Da, S., & Gm, W. (1976) · PubMed · Cited by 15
Os, I., Os, A., Sandset, P. M., Bølling, S., Seljeflot, I., Djurovic, S., & Westheim, A. S. (2002) · Cardiology · doi:10.1159/000064667 · Cited by 15
Hormone replacement therapy: discrepancies between evidence and recommendations
Hemminki, E. (2000) · Scandinavian Journal of Public Health · doi:10.1177/140349480002800201 · Cited by 13
Merz, C. N. B., SHUFELT, C. L., Johnson, B. D., Azziz, R., & Braunstein, G. D. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.01.003 · Cited by 10
Khan, M. A., Hlatky, M. A., Liu, M. W., Lin, F., Rogers, W. J., & Shlipak, M. G. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00121-8 · Cited by 10
Bittner, V., Tripputi, M., Hsia, J. A., Gupta, H., & Steffes, M. W. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.025 · Cited by 9
Simon, J. A. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(03)00113-3 · Cited by 9
LOWE, J. M. (2002) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.7.5.137 · Cited by 7
(2011) · Medical Entomology and Zoology
Cited by
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Authors/Task Force Members:, Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,384
Sarcopenia: Aging-Related Loss of Muscle Mass and Function
Larsson, L., Degens, H., Li, M., Salviati, L., Lee, Y. I., Thompson, W., Kirkland, J. L., & Sandri, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00061.2017 · Cited by 1,797
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
Metadata
- Authors
- Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2005-07-20
- Volume
- 1
- Issue
- 3
- Pages
- CD004143-CD004143
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1892432125
- Cited by
- 582
- References
- 246
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.